Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,479,730

« Back to Dashboard
Patent 8,479,730 protects SEEBRI, UTIBRON, and ARCAPTA NEOHALER, and is included in three NDAs.

This patent has thirty-one patent family members in twenty-nine countries.

Summary for Patent: 8,479,730

Title:Inhaler device
Abstract: An inhaler device (1) for powdered medicaments. The device (1) has a body (5) that has a recess (50) for holding a capsule containing a powdered medicament to be inhaled, at least one air passage (90) that is tangentially disposed to the recess (50) , and a mouthpiece (30) that includes a coaxially disposed inhalation passage (70) that communicates with the recess (50) of the body (5). The body (5) has a pair of opposed spring (105) biased push-buttons (40) that each include at least one piercing element (95) for piercing the capsule when loaded in the recess (50). The medicament is released from the pierced capsule when air is drawn through the air passage(s) (90) into the recess (50) and swirled about therein. The mouthpiece (30) is pivotally attached to the edge of the body (5) so that it is pivotable between an open loading position and a closed dispensing position about an axis that is perpendicular to the longitudinal axis of the inhaler (1).
Inventor(s): Ziegler; Dominik (Basel, CH), Smetham; Grant (Cambridge, GB), Citterio; Mauro (Osnago, IT)
Assignee: Novartis AG (Basil, CH)
Application Number:11/568,466
Patent Claim Types:
see list of patent claims
Dosage form; Delivery; Device; Compound;
Patent Metrics:
Source: PatentQuant.com
Field: Medical technology
Back Citations: 26th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
POWDER;INHALATION207923-001Oct 29, 2015RXYes8,479,730Oct 11, 2028Y
Novartis Pharms Corp
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYes8,479,730Oct 11, 2028Y
indacaterol maleate
POWDER;INHALATION022383-001Jul 1, 2011RXYes8,479,730Oct 11, 2028Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,479,730

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0410712.4May 13, 2004
PCT Information
PCT FiledMay 12, 2005PCT Application Number:PCT/EP2005/005182
PCT Publication Date:December 01, 2005PCT Publication Number: WO2005/113042

International Patent Family for Patent: 8,479,730

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Peru00982006<disabled in preview>
New Zealand550625<disabled in preview>
Norway334854<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.